Key result
POLARx cryoballoon matches Arctic Front Advance PRO with 100% PVI success but longer procedural times.
Why the study?
POLARx is a novel cryoballoon designed to improve outcomes, but clinical evidence evaluating its procedural safety and efficacy was restricted to a case report.
Does the novel POLARx cryoballoon improve procedural efficacy and safety compared to the historical AFAP cryoballoon in patients undergoing atrial fibrillation ablation?
Population
Consecutive patients undergoing AF cryoablation
Comparison
POLARx cryoballoon vs historical Arctic Front Advance PRO cohort
Design
Single-center cohort study
Authors
Loading...
Similar PVI success and safety with POLARx versus AFAP in this cohort; hypothesis-generating and requires randomized confirmation before practice change.
Cohort
No
Does the novel POLARx cryoballoon improve procedural efficacy and safety compared to the historical AFAP cryoballoon in patients undergoing atrial fibrillation ablation?
Absolute Event Rate: 100% vs 100%
The novel POLARx cryoballoon demonstrated similar procedural efficacy (100% pulmonary vein isolation) and safety compared to the established AFAP platform, though it was associated with longer procedural times.
Kochi et al. (2021) conducted a cohort in Atrial fibrillation. POLARx cryoballoon vs. Arctic Front Advance PRO (AFAP) cryoballoon was evaluated on All pulmonary veins isolation. The POLARx cryoballoon achieved 100% pulmonary vein isolation, identical to the Arctic Front Advance PRO, with similar complication rates (0% vs. 5.7%, p=0.39) but longer procedural times.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: